4-methyl-4-(pyrrolidin-1-yl)piperidine | 1061683-29-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-methyl-4-(pyrrolidin-1-yl)piperidine
• 英文别名: 4-methyl-4-pyrrolidin-1-ylpiperidine
• CAS: 1061683-29-1
• 化学式: C₁₀H₂₀N₂
• 分子量: 168.282
• InChiKey: VLZSQQMKOKWEFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-溴-3-甲氧基-5-硝基苯 、 4-methyl-4-(pyrrolidin-1-yl)piperidine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 以67%的产率得到1–(3-methoxy-5-nitrophenyl)-4-methyl-4-(pyrrolidin-1-yl)piperidine
  参考文献：
  名称：

  Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors

  摘要：

  The TAM (Axl, Mer, and Tyro3) family is implicated in the survival and chemoresistance of tumours and has emerged as a potential therapeutic target. A novel series of 7-aryl-2-anilino-pyrrolopyrimidines were identified as potent Axl/Mer tyrosine kinase inhibitors without significant inhibition of Tyro3. A representative compound27exhibited IC(50)values of 2 nM and 16 nM for Mer and Axl, respectively, and considerable inhibition for Mer phosphorylation in cells. Docking studies suggested that the formation of a salt bridge between the nitrogen of the aniline moiety with ASP678 of the Mer kinase domain as well as an interaction with the hinge region that most kinase inhibitors have in common would be essential to retain activity. These results could provide useful information for finding promising inhibitors of Axl/Mer for the treatment of cancer.

  DOI：

  10.1080/14756366.2020.1825407

文献信息

• [EN] BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE<br/>[FR] COMPOSÉS PYRIMIDINES BICYCLIQUES INHIBITEURS DE PI3K SÉLECTIFS POUR P110 DELTA, ET PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2010138589A1

  公开（公告）日：2010-12-02

  Formula (I) ((Ia) and (Ib)) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式（I）（（Ia）和（Ib））化合物，其中（i）X1为N且X2为S，（ii）X1为CR7且X2为S，（iii）X1为N且X2为NR2，或（iv）X1为CR7且X2为O，包括其立体异构体，互变异构体，代谢物和药用可接受盐，用于抑制PI3K的δ异构体，并用于治疗由脂质激酶介导的疾病，如炎症，免疫和癌症。公开了使用公式（I）化合物进行体外，体内和体内诊断，预防或治疗哺乳动物细胞中的这类疾病或相关病理状况的方法。
• AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS
  申请人：Binch Hayley

  公开号：US20100137305A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

  本发明涉及作为Aurora蛋白激酶抑制剂的化合物。该发明还提供包含这些化合物的药用可接受组合物，以及在治疗各种疾病、状况和障碍中使用这些化合物和组合物的方法。该发明还提供了制备本发明化合物的方法。
• [EN] AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] AMINOPYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2008115973A2

  公开（公告）日：2008-09-25

  [EN] The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
  [FR] La présente invention concerne des composés utiles en tant qu'inhibiteurs de la protéine kinases d'Aurora. L'invention propose également des compositions pharmaceutiquement acceptables comprenant ces composés et des procédés d'utilisation des composés et compositions dans le traitement de diverses maladies, affections et troubles. L'invention propose également des procédés de préparation des composés de l'invention.